Compositions of aldh1a1 inhibitors and methods of use in treating cancer
AssigneeIndiana University Research and Technology Corporation
InventorsThomas D. Hurley, Daniela Matei
Life of this patent
Estimating the term…
Abstract
The present invention provides inhibitors of ALDH1A1 activity which have substantially no effect on either ALDH2 or ALDH3A1. Compositions and methods of use, as well as methods to treat cancer using the ALDH1A1 inhibitors, are also provided.
Claims16
A pharmaceutical composition comprising
- (a) a therapeutically effective amount of an inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1) selected from the group consisting of
- CM001 1.1 μM
- CM045 2.5 μM
- CM009 5.3 μM
- CM047 0.31 μM
- CM010 1.3 μM
- CM053 0.21 μM
- CM020 0.45 μM
- CM055 0.24 μM
- CM025 2.1 μM
- CM056 5.4 μM
- CM026 0.80 μM
- CM057 0.92 μM
- CM028 2.0 μM
- CM302 1.1 μM
- CM037 4.6 μM
- CM306 3.5 μM
- CM038 0.26 μM
- CM307 0.57 μM
- CM039 0.41 μM
- CM037a 23 μM
- CM037g 3.3 μM
- .
- or its pharmaceutically acceptable salt or a solvate thereof, and
- (b) a pharmaceutically suitable carrier.
A kit comprising a therapeutically effective amount of at least one inhibitor of aldehyde dehydrogenase (ALDH1A1) selected from the group consisting of
- CM001 1.1 μM
- CM045 2.5 μM
- CM009 5.3 μM
- CM047 0.31 μM
- CM010 1.3 μM
- CM053 0.21 μM
- CM020 0.45 μM
- CM055 0.24 μM
- CM025 2.1 μM
- CM056 5.4 μM
- CM026 0.80 μM
- CM057 0.92 μM
- CM028 2.0 μM
- CM302 1.1 μM
- CM037 4.6 μM
- CM306 3.5 μM
- CM038 0.26 μM
- CM307 0.57 μM
- CM039 0.41 μM
- CM037a 23 μM
- CM037g 3.3 μM
- or its pharmaceutically acceptable salt or a solvate thereof, and instructions for use.
A method of inhibiting aldehyde dehydrogenase 1A1 (ALDH1A1) in a subject, the method comprising administering a therapeutically effective amount of a composition comprising a compound selected from the group consisting of
- CM001 1.1 μM
- CM045 2.5 μM
- CM009 5.3 μM
- CM047 0.31 μM
- CM010 1.3 μM
- CM053 0.21 μM
- CM020 0.45 μM
- CM055 0.24 μM
- CM025 2.1 μM
- CM056 5.4 μM
- CM026 0.80 μM
- CM057 0.92 μM
- CM028 2.0 μM
- CM302 1.1 μM
- CM037 4.6 μM
- CM306 3.5 μM
- CM038 0.26 μM
- CM307 0.57 μM
- CM039 0.41 μM
- CM037a 23 μM
- CM037g 3.3 μM
- or an analog thereof, and a pharmaceutically acceptable carrier to the subject, wherein the ALDH1A1 in the subject is inhibited.
Dependencies are inferred from the claim text.